Investing in Adaptimmune Therapeutics plc (ADAP) is a safe bet with a significant edge

In the latest session, Adaptimmune Therapeutics plc (NASDAQ: ADAP) closed at $1.15 up 3.60% from its previous closing price of $1.11. In other words, the price has increased by $+0.0400 from its previous closing price. On the day, 705758 shares were traded. ADAP stock price reached its highest trading level at $1.1699 during the session, while it also had its lowest trading level at $1.0900.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



For a deeper understanding of Adaptimmune Therapeutics plc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.00 and its Current Ratio is at 4.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On November 09, 2022, Mizuho Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $9.

On May 28, 2021, Barclays started tracking the stock assigning a Underweight rating and target price of $4.Barclays initiated its Underweight rating on May 28, 2021, with a $4 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 31 when Piccina Cintia sold 11,890 shares for $1.87 per share. The transaction valued at 22,230 led to the insider holds 19,535 shares of the business.

Rawcliffe Adrian sold 10,057 shares of ADAP for $18,686 on Jan 17. The Chief Executive Officer now owns 13,351 shares after completing the transaction at $1.86 per share. On Jan 17, another insider, Bertrand William C JR, who serves as the Chief Operating Officer of the company, sold 4,440 shares for $1.86 each. As a result, the insider received 8,250 and left with 7,264 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 7.45 while its Price-to-Book (P/B) ratio in mrq is 2.30.

Stock Price History:

Over the past 52 weeks, ADAP has reached a high of $2.65, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is 1.6618, while the 200-Day Moving Average is calculated to be 1.6997.

Shares Statistics:

For the past three months, ADAP has traded an average of 499.00K shares per day and 1.42M over the past ten days. A total of 165.31M shares are outstanding, with a floating share count of 165.11M. Insiders hold about 0.12% of the company’s shares, while institutions hold 70.30% stake in the company. Shares short for ADAP as of Jan 30, 2023 were 2.8M with a Short Ratio of 2.89M, compared to 2.95M on Dec 29, 2022.

Earnings Estimates

There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.25 for the current quarter, with a high estimate of -$0.2 and a low estimate of -$0.27, while EPS last year was -$0.24. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.14 and low estimates of -$0.26.

Analysts are recommending an EPS of between -$1.05 and -$1.12 for the fiscal current year, implying an average EPS of -$1.1. EPS for the following year is -$0.78, with 6 analysts recommending between -$0.55 and -$1.

Revenue Estimates

A total of 8 analysts believe the company’s revenue will be $4.12M this quarter.It ranges from a high estimate of $10M to a low estimate of $500k. As of the current estimate, Adaptimmune Therapeutics plc’s year-ago sales were $1.42M, an estimated increase of 190.80% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $3.9M, an increase of 9.10% less than the figure of $190.80% in the same quarter last year. There is a high estimate of $6M for the next quarter, whereas the lowest estimate is $2M.

A total of 8 analysts have provided revenue estimates for ADAP’s current fiscal year. The highest revenue estimate was $26.1M, while the lowest revenue estimate was $16.6M, resulting in an average revenue estimate of $20.23M. In the same quarter a year ago, actual revenue was $6.15M, up 229.00% from the average estimate.